Mar Vista Investment Partners LLC Boosts Stock Holdings in Stryker Corporation $SYK

Mar Vista Investment Partners LLC grew its position in Stryker Corporation (NYSE:SYK) by 22.0% during the 4th quarter, HoldingsChannel.com reports. The fund owned 101,173 shares of the medical technology company’s stock after buying an additional 18,216 shares during the quarter. Stryker makes up about 3.3% of Mar Vista Investment Partners LLC’s portfolio, making the stock its 15th largest holding. Mar Vista Investment Partners LLC’s holdings in Stryker were worth $35,559,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. &PARTNERS lifted its holdings in Stryker by 14.1% in the 4th quarter. &PARTNERS now owns 48,414 shares of the medical technology company’s stock valued at $17,024,000 after purchasing an additional 5,995 shares in the last quarter. Mangrove Partners IM LLC purchased a new stake in shares of Stryker during the fourth quarter worth $983,000. Persistent Asset Partners Ltd acquired a new stake in shares of Stryker in the fourth quarter valued at about $188,000. Bank of Marin lifted its stake in shares of Stryker by 5.8% in the fourth quarter. Bank of Marin now owns 2,281 shares of the medical technology company’s stock worth $802,000 after buying an additional 125 shares in the last quarter. Finally, Opal Capital LLC acquired a new position in Stryker during the fourth quarter worth about $255,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Price Performance

Shares of SYK stock opened at $310.71 on Wednesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market capitalization of $119.11 billion, a PE ratio of 35.96, a price-to-earnings-growth ratio of 1.97 and a beta of 0.78. The firm’s 50-day moving average is $315.51 and its two-hundred day moving average is $342.88. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. Stryker had a return on equity of 23.42% and a net margin of 13.20%.The firm’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Buying and Selling at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 323,264 shares of company stock worth $100,659,489 over the last quarter. 4.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on SYK. Weiss Ratings cut shares of Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Needham & Company LLC dropped their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research report on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research report on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 price objective on Stryker in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $395.33.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.